Ovarian Cancer
Conditions
Keywords
Ovarian, debulked, recurrent, Stage III, Stage IV
Brief summary
This is a pilot study aimed to test the feasibility and safety of administering combination chemotherapy with paclitaxel (both intravenously and intraperitoneally) and cisplatin (intraperitoneally) plus whole abdominal hyperthermia every 3 weeks in the treatment of optimally debulked, advanced or recurrent ovarian, primary peritoneal, and fallopian tube cancer patients.
Detailed description
Day 1 of each 21 day Cycle: Paclitaxel 175 mg/m2 IV (infused over 3 hours) Day 1 or 2 of each Cycle Adequate IV hydration with normal saline (1000 ml recommended)followed by intraperitoneal infusion of 500 ml normal saline through the IP port. Cisplatin 75 mg/m2 reconstituted in 500 ml NS warmed to 37 degrees Celsius is infused IP (30 minute infusion)followed immediately by whole abdominal hyperthermia Abdominal hyperthermia will be delivered using the BSD 2000 ellipse system to target temperatures of 40-42 degrees Celsius monitored via rectally and vaginally continuing for no greater than 60 minutes after maximal 30 minute warm-up phase. Total duration of hyperthermia will be no greater than 90 minutes. Day 8: Paclitaxel 60 mg/m2 IP. Paclitaxel will be diluted and filtered initially in 1000 ml of normal saline or D5W warmed to 37 degrees Celsius. For IP administration, the patient must receive an additional 1000 ml of normal saline degrees Celsius in the peritoneal cavity. Cycles will be repeated every 3 weeks x 6 cycles. Patients will be followed until disease progression/recurrence or death.
Interventions
DEVICEHyperthermia
Every 3 weeks
Sponsors
Mark Dewhirst
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 72 Years
Healthy volunteers
No
Inclusion criteria
* Histologically diagnosed Stage III or Stage IV advanced, persistent, or recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer * Optimal debulking (\< 1cm residual disease) of their disease within 6 weeks of the start of the study * Patients must have received no more than 2 prior chemotherapy regimens with at least 4 weeks since prior chemotherapy * GOG performance status 0, 1, or 2 * Patients must have normal organ and marrow function defined as: * absolute neutrophil count \>1,500/mcL * platelets \>100,000/mcL * total bilirubin and creatinine \<1.5 X institutional upper limit of normal(ULN) * AST(SGOT)/ALT(SGPT)\<3 X institutional ULN
Exclusion criteria
* Patients with biochemical recurrences or evidence of measurable disease * Patients with suboptimal (\>1 cm) residual disease * Patients who have had chemotherapy within 4 weeks prior * Receiving any investigational agents * Known brain metastases * Epithelial ovarian carcinoma of low malignant potential (borderline carcinomas) * Uncontrolled intercurrent illness * Prior radiation therapy * History of other invasive or pre-invasive malignancies (except non-melanoma skin cancer) within the past 5 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Toxicity | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Clinically free of disease. Response definitions will be based on CA-125, clinical assessment, CT imaging | 1 year |
Outcome results
None listed